Oragenics Chases Vaccine for Niche Markets

UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, seeks to be a major player in the Super Bowl of the pharmaceutical industry: a COVID-19 vaccine.

Dialectic Therapeutics Receives FDA Clearance of IND Application for for Its Lead Product Candidate To Treat Cancer

UF startup Dialectic Therapeutics, Inc., a Texas-based biotechnology company focused on creating innovative new technologies to treat cancer, announced that the U.S. Food and Drug Administration (FDA) has concluded that Dialectic may proceed with its clinical investigation for its lead product candidate, DT2216, a unique compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD) technology.